Latest SELLAS Life Sciences News & Updates

See the latest news and media coverage for SELLAS. We track all announcements, press releases, and industry mentions in real time, all in one place.

SELLAS Life Sciences (SELLAS)

Late-stage clinical biopharmaceutical company

sellaslifesciences.com

Headquarters: New York, United States
Founded year: 2012
Company type: Public company
Number of employees: 15–50

Last updated Today

Latest news about SELLAS Life Sciences (SELLAS)

In short: SELLAS advanced its clinical pipeline, focusing on the Phase 3 REGAL trial and SLS009 studies while managing its financial and regulatory milestones.

Company announcements

May 12 SELLAS

SELLAS reports Q1 2026 financial results and corporate update

Cash position $107.1M, REGAL trial at 78 events, SLS009 Phase 2 dosing ongoing.

March 19 SELLAS

SELLAS reports full year 2025 financial results and corporate update

Cash position $71.8M; net loss $26.9M; progress in GPS and SLS009 trials.

March 12 SELLAS

SELLAS enrolls first patient in first-line AML trial of SLS009

The randomized Phase 2 study will enroll 80 patients unlikely to benefit from standard therapy.

January 14 SELLAS

SELLAS expands SLS009 clinical program into Europe via IMPACT-AML agreement

The collaboration aims to enable broader U.S. and European patient enrollment for SLS009 in frontline AML.

Media coverage

May 14 The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Solid Biosciences (SLDB), SELLAS Life Sciences Group (SLS) and Legend Biotech (LEGN)

Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.

May 13 MSN

SLS on track to clock best week in over 4 months: Retail divided between stock drop or multibagger status amid upcoming leukemia trial readout

So far this week, SLS has gained nearly 30%, on track for its best week since the week ended Jan 2, if gains hold. ・SELLAS...

May 13 Yahoo Finance

SELLAS Life Sciences (SLS) Is Up 50.5% After Pivotal AML Trial Nears Readout And Adds Funding Flexibility – Has...

Earlier in 2026, SELLAS Life Sciences Group, Inc. reported a US$8.41 million net loss for the first...

May 13 MSN

SELLAS rises as Q1 update suggests lead program nears final analysis

SELLAS Life Sciences (SLS) added ~16% in extended trading on Wednesday after the cancer drug developer, with its Q1 2026 results, indicated that it will...

Never miss news about SELLAS

Track SELLAS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

SELLAS competitors & trending companies

Browse news for competitors to SELLAS and other trending companies.